Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

{
  "signal_id": "f009ec76-274b-36d0-bc21-2117d82b51c5",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-21T10:24:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/21/3365319/0/en/novo-s-cagrisema-delivers-superior-weight-loss-versus-tirzepatide-in-reimagine-5-trial.html",
    "title": "Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial",
    "excerpt": "Bagsværd, Denmark, 21 September 2026 – Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo's next innovation in weight management and type 2 diabetes. The findings were highlighted at Novo’s Capital Markets Day investor briefing. In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1%, respectively. CagriSema also confirmed non-inferior reduction in HbA 1c (1.71%) versus tirzepatide (1.67%). In REDEFINE 9, CagriSema 1.0 mg/1.0 mg provided a weight reduction of 21.0% versus 2.0% for placebo, and the primary superiority endpoint was met. CagriSema also showed greater improvements than placebo across prespecified supportive endpoints, including systolic blood pressure, waist-to-height ratio and fasting lipid profile. “The results from CagriSema are very encouraging, demonstrating the strong potency of the combination of semaglutide and cagrilintide. With only 1.0 mg/1.0 mg, CagriSema shows superior weight loss versus tirzepatide 5 mg as well as strong results across obesity and type 2 diabetes,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “CagriSema remains investigational...",
    "product": "CagriSema",
    "summary": "Novo Nordisk's investigational weight management drug, CagriSema, demonstrated superior weight loss compared to tirzepatide in its phase 3 REIMAGINE 5 trial.",
    "location": "Bagsværd, Denmark",
    "planning": true,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/f87e6f85-3e50-4571-b9e5-8f683431f855",
    "confidence": 0.95,
    "product_data": {
      "name": "CagriSema",
      "full_text": "once-weekly CagriSema (cagrilintide and semaglutide), an investigational product",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-21T10:24:00Z",
    "location_data": [
      {
        "city": "Bagsværd",
        "state": "Capital Region of Denmark",
        "region": "Northern Europe",
        "country": "Denmark",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1%, respectively."
  }
}

curl https://signals.autobound.ai/v1/signals/f009ec76-274b-36d0-bc21-2117d82b51c5 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'